Type:Injection
Generic Name:Dacarbazine
Manufacturer:Beacon Pharmaceuticals Ltd.
Price:৳1000.00
Metastatic melanoma, Hodgkin's disease, Soft tissue sarcoma
IV Preparation Reconstitute with a 9.9 mL (100 mg vial) or 19.7 mL (200 mg vial) of SWI to obtain a 10 mg/mL soln For infusion, dilute with D5W or NS up to 250 mL IV Administration IVP over 1 min (may be irritant & painful) OR infusion over 15-60 min
Intravenous Metastatic melanoma Adult: 2-4.5 mg/kg daily for 10 days, repeat at 4-wk intervals or 200-250 mg/m2 BSA daily for 5 days, repeat at 3-wk intervals or 850 mg/m2 BSA by infusion, repeat at 3-wk intervals. Hodgkin's disease Adult: 150 mg/m2 BSA daily for 5 days, repeat every 4 wk or 375 mg/m2 BSA every 15 days in combination with other agents. Soft tissue sarcoma Adult: 250 mg/m2 BSA daily for 5 days repeated every 3 wk. Usually given with doxorubicin.
Hodgkin's Disease With other antineoplastics, eg ABVD Dosage dependent on protocol150 mg/m² IV qDay for 5 days, repeat q4Weeks OR 375 mg/m² IV on Day 1; repeat every 15 Days
Bone marrow suppression; hypersensitivity.
The exact mechanism of action is still unclear but it appears to form methylcarbonium ions that attack nucleophilic groups by attaching to the 7-position of guanine on DNA. It also cross-links DNA strands leading to inhibition of DNA, RNA and protein synthesis.
Hepatic or renal impairment. Pregnancy, lactation. Lactation: not known if excreted in breast milk, do not nurse
>10% Nausea (>90%),Vomiting(>90%),Injection site pain,Leukopenia,Thrombocytopenia 1-10% Alopecia,Rash,Photosensitivity,Anorexia,Metallic taste,Flu-like syndrome Frequency Not Defined Anaphylaxis,Photosensitivity (rare),Cerebral hemorrhage,Seizure,Myelosuppression,Hepatic necrosis,Hepatic vein thrombosis,Hepatotoxicity Potentially Fatal: Myelosuppression; hepatotoxicity, anaphylaxis.
Pregnancy Category: C Lactation: not known if excreted in breast milk, do not nurse
Impairs immune response to vaccines; possible infection after admin of live vaccines. Effect increased by CYP1A2 inhibitors e.g. amiodarone, ciprofloxacin, fluvoxamine, ketoconazole, lomefloxacin, ofloxacin and rofecoxib. Effect decreased by CYP1A2 inducers e.g. aminoglutethimide, carbamazepine, phenobarbital and rifampicin.